

Pharmacist-led smoking cessation programs: A comprehensive review of effectiveness, implementation models, and future directions

Oluwaseyi Inumidun Alli ^{1,*} and Samuel Ajibola Dada ²

¹ *Novartis Nigeria Limited, Nigeria.*

² *Alltymz Pharmacy Ltd, Port-Harcourt, Nigeria.*

International Journal of Science and Technology Research Archive, 2022, 03(02), 297-304

Publication history: Received on 02 October 2022; revised on 19 November 2022; accepted on 22 November 2022

Article DOI: <https://doi.org/10.53771/ijstra.2022.3.2.0129>

Abstract

Pharmacist-led smoking cessation programs have emerged as effective interventions in addressing the global tobacco epidemic, leveraging the accessibility and expertise of pharmacists to provide tailored behavioral counseling, pharmacological support, and follow-up care. This review examines the effectiveness of these programs, highlighting their ability to achieve higher quit rates, improved patient satisfaction, and cost-effectiveness compared to traditional methods. Various implementation models, including those in community pharmacies, hospital settings, and telehealth platforms, are explored, along with the challenges of scaling these interventions, such as limited awareness, training gaps, and inadequate reimbursement. Future directions emphasize innovations in digital tools, personalized medicine, artificial intelligence, and policy and funding support to enhance program reach and sustainability. Recommendations are provided for pharmacists, healthcare systems, and policymakers to address barriers, expand access, and foster collaboration, ultimately integrating pharmacist-led smoking cessation into mainstream healthcare as a critical strategy for tobacco control.

Keywords: Pharmacist-led programs; Smoking cessation; Behavioral counseling; Public health; Telehealth interventions; Personalized medicine

1. Introduction

Smoking remains a major global health challenge, causing preventable diseases and significant premature deaths (Bilano et al., 2015). According to the World Health Organization (WHO), tobacco use kills more than eight million people annually, with over seven million of these deaths attributed to direct smoking and about 1.2 million resulting from exposure to secondhand smoke (Organization, 2017). The harmful effects of smoking extend beyond individual health, leading to broader societal and economic burdens, including increased healthcare costs, reduced workplace productivity, and diminished quality of life for smokers and their families. Addressing tobacco use is a critical priority for public health systems worldwide, necessitating comprehensive and accessible cessation interventions (Perez-Warnisher, de Miguel, & Seijo, 2019).

Pharmacists are uniquely positioned within healthcare systems to contribute meaningfully to smoking cessation efforts (O'Reilly, Frederick, & Palmer, 2019). With their extensive knowledge of medications and their accessibility in both urban and rural settings, pharmacists serve as a critical first point of contact for many individuals seeking healthcare advice (Schafer, Gill, Sherman, McNicholl, & Hawkins, 2016). Unlike other healthcare professionals who often require scheduled appointments, pharmacists are available without prior arrangements, making them highly accessible resources for smoking cessation support. Furthermore, their ability to develop close, ongoing relationships with

* Corresponding author: Oluwaseyi Inumidun Alli

patients enables them to provide continuous support throughout the cessation journey, enhancing the likelihood of successful outcomes (Ogunbayo, Schafheutle, Cutts, & Noyce, 2015).

In recent years, pharmacist-led smoking cessation programs have gained traction as an effective approach to helping individuals quit smoking. These programs typically involve a combination of patient education, behavioral counseling, and pharmacotherapy management (Atif et al., 2020). Pharmacists are also trained to identify potential barriers to cessation, such as nicotine dependence and withdrawal symptoms, and to tailor interventions to meet the specific needs of each patient. This individualized approach has shown promise in increasing quit rates and improving patient satisfaction compared to standard cessation methods (Hilts, Corelli, Vernon, & Hudmon, 2022).

This review aims to comprehensively examine pharmacist-led smoking cessation programs by addressing their effectiveness, exploring various implementation models, and identifying key factors that contribute to their success. By synthesizing current evidence, this paper seeks to advocate for the integration of pharmacist-led cessation services into broader healthcare frameworks. Additionally, the review will highlight opportunities for innovation and collaboration, emphasizing the critical role of pharmacists in reducing the global tobacco burden.

2. Effectiveness of Pharmacist-Led Smoking Cessation Programs

Smoking cessation is a multifaceted challenge, requiring tailored interventions to address the physiological, psychological, and behavioral dimensions of nicotine addiction. Pharmacist-led smoking cessation programs have emerged as effective strategies to assist individuals in quitting smoking, supported by robust evidence from clinical trials and observational studies. These programs, characterized by the provision of personalized counseling, medication management, and continuous follow-up, have consistently demonstrated favorable outcomes across various settings.

2.1. Overview of Evidence from Clinical Trials and Observational Studies

Numerous clinical trials and observational studies underscore the effectiveness of pharmacist-led smoking cessation interventions, highlighting their potential to achieve substantial and sustained quit rates across diverse populations (Pettit, Pope, Neuner, Lash, & Bernstein, 2022). In a systematic review, pharmacist-driven programs demonstrated significantly higher abstinence rates compared to standard care or minimal interventions (Greer et al., 2016). The review revealed that individuals participating in pharmacist-led interventions were more likely to achieve sustained abstinence at six and twelve months, emphasizing the long-term efficacy of these programs.

A landmark study conducted in community pharmacies provided compelling evidence of success. Participants who received structured behavioral counseling combined with nicotine replacement therapy from trained pharmacists reported a 23% higher quit rate at six months compared to those relying on self-help materials alone. This finding underscores the value of personalized support and expertise in enhancing cessation outcomes (Patel & Steinberg, 2016).

Similarly, a randomized controlled trial in a hospital outpatient setting compared pharmacist-led smoking cessation interventions to physician-led counseling sessions. The study found that pharmacist-driven programs achieved a 30% quit rate at one year, surpassing the outcomes of physician-led interventions. This result highlights the clinical competence of pharmacists and suggests that their accessibility and frequent interactions with patients may contribute to superior results (Register, Harrington, Agne, & Cherrington, 2016).

Observational studies further corroborate these findings. A multicenter study evaluating smoking cessation services in urban and rural settings found that pharmacist-led programs consistently outperformed alternative interventions in terms of quit rates and patient satisfaction. Participants reported high levels of engagement, citing the pharmacists' ability to provide personalized recommendations, monitor progress, and address barriers such as withdrawal symptoms and relapse (Rukavena, 2021). Pharmacist-led interventions have also proven effective in specific patient groups, such as individuals with chronic conditions exacerbated by smoking. For instance, a study focusing on patients with cardiovascular disease demonstrated that pharmacist-led smoking cessation services resulted in a 35% quit rate at six months, significantly reducing the risk of further complications (Abdulsalim et al., 2018).

These findings collectively validate the critical role of pharmacists as providers of smoking cessation services. Their accessibility, expertise in pharmacotherapy, and ability to offer ongoing support position them as pivotal contributors to tobacco control efforts. As healthcare systems increasingly emphasize preventative care, pharmacist-led programs represent a scalable and evidence-based approach to reducing smoking prevalence and improving public health outcomes.

2.2. Key Outcomes: Quit Rates, Patient Satisfaction, and Cost-Effectiveness

The primary measure of success in smoking cessation programs is the quit rate, defined as the proportion of individuals who achieve sustained abstinence over a specified period. Pharmacist-led programs have consistently achieved quit rates ranging from 20% to 35%, depending on the intensity of the intervention and the patient population. These rates are particularly significant given the challenges associated with quitting smoking, including nicotine dependence, withdrawal symptoms, and psychosocial triggers.

In addition to quit rates, patient satisfaction is a critical indicator of program success. Studies have shown that individuals participating in pharmacist-led programs report high levels of satisfaction, citing the convenience, accessibility, and personalized care provided by pharmacists (Greenhalgh, Macfarlane, Steed, & Walton, 2016). Patients frequently express appreciation for the ongoing support and encouragement offered by pharmacists, which they perceive as instrumental in their journey to quit smoking. The trust and rapport built between pharmacists and patients further enhance the effectiveness of these programs (Greer et al., 2016).

Cost-effectiveness is another key outcome that supports the implementation of pharmacist-led interventions. Smoking cessation not only improves individual health outcomes but also reduces healthcare expenditures associated with tobacco-related diseases (Brett, Yeung, & Ford, 2019). Economic evaluations have demonstrated that pharmacist-led programs are cost-effective, often yielding a favorable return on investment due to reduced healthcare costs and improved productivity among individuals who quit smoking. A study in the United Kingdom estimated that every pound spent on pharmacist-led cessation services saved the healthcare system three pounds in treatment costs for smoking-related illnesses (Alabkal, 2021).

When compared to other smoking cessation interventions, pharmacist-led programs often demonstrate superior outcomes. Traditional methods, such as self-help materials or brief advice from general practitioners, have relatively low success rates, typically ranging from 5% to 10%. While these approaches may reach a larger audience, their limited intensity and lack of follow-up reduce their overall effectiveness (Ciccolo & Busch, 2015).

In contrast, programs involving pharmacists provide a structured and comprehensive approach to smoking cessation. Unlike group therapy sessions, which may not cater to individual needs, pharmacist-led interventions are tailored to each patient's unique circumstances, preferences, and challenges. Moreover, pharmacists can seamlessly integrate pharmacological support, such as nicotine replacement therapy or prescription medications, into their counseling, ensuring that patients receive both behavioral and pharmacological assistance (Mattingly & Mattingly II, 2018).

Pharmacist-led interventions also outperform many digital and telehealth-based cessation programs, particularly in terms of patient engagement and adherence. While technology-driven solutions can complement traditional methods, the face-to-face interaction and personalized care offered by pharmacists remain unparalleled. This human element motivates individuals to quit and fosters accountability, a critical factor in achieving long-term success (VanFrank & Presley-Cantrell, 2021).

3. Implementation Models and Strategies

Implementing pharmacist-led smoking cessation programs requires thoughtful planning and a clear understanding of the models and strategies that best suit diverse healthcare settings. When effectively implemented, these programs can maximize their reach and impact on public health. This section examines various delivery models, explores the critical role of training and resources, highlights collaboration with other healthcare providers, and discusses the challenges that may hinder successful implementation.

3.1. Description of Different Pharmacist-Led Program Models

Pharmacist-led smoking cessation programs can be delivered through various models, depending on the healthcare setting and population needs.

In-Community Pharmacies: Community pharmacies are among the most common and accessible settings for pharmacist-led cessation services. Patients can receive walk-in consultations, personalized counseling, and pharmacotherapy management in these locations (O'Reilly et al., 2019). These programs are particularly advantageous in rural and underserved areas, where access to other healthcare professionals may be limited. Community pharmacies often serve as the first point of contact for individuals considering quitting smoking, making them a strategic location for intervention (Brett et al., 2019).

Hospital Settings: In hospital-based programs, pharmacists work as part of multidisciplinary teams to provide smoking cessation services to inpatients and outpatients. This model is especially relevant for patients with smoking-related illnesses, such as cardiovascular or respiratory diseases, who are already engaged with the healthcare system. Hospital-based pharmacists can use "teachable moments" to motivate patients to quit and provide follow-up support during recovery (Trapskin et al., 2022).

Telehealth and Digital Platforms: Telehealth has expanded the reach of pharmacist-led smoking cessation programs, particularly during the global shift toward virtual healthcare delivery. These platforms enable pharmacists to provide counseling, monitor progress, and recommend medications through video calls or mobile apps (Crilly & Kayyali, 2020). Digital tools, such as automated reminders and virtual coaching, can supplement telehealth services, ensuring consistent patient engagement. Telehealth models are especially valuable for individuals with mobility issues or those living in remote areas (Gershkowitz, Hillert, & Crotty, 2021).

Workplace and Corporate Wellness Programs: Employers increasingly recognize the benefits of supporting smoking cessation among their workforce. Pharmacists can deliver on-site or virtual programs tailored to employees, offering education, counseling, and pharmacological support as part of corporate wellness initiatives. These programs improve employee health, enhance workplace productivity, and reduce absenteeism (McCart, 2017).

3.2. Training, Resources, and Collaboration with Other Healthcare Providers

Successful implementation of pharmacist-led programs hinges on the availability of adequate training and resources. Comprehensive training equips pharmacists with the skills to assess patients' readiness to quit, develop individualized cessation plans, and address challenges such as withdrawal symptoms and relapse (Jones et al., 2017). Training should include evidence-based behavioral counseling techniques, such as motivational interviewing, and knowledge of available pharmacotherapies. Continuing education programs and certification courses can ensure pharmacists remain updated on the latest guidelines and practices (Novins, Croy, Moore, & Rieckmann, 2016).

Access to resources, such as patient education materials, standardized assessment tools, and digital tracking systems, further enhances the quality of these programs. Providing pharmacists with user-friendly technology can streamline patient data collection, facilitate follow-ups, and measure program outcomes effectively (A. K. Mohiuddin, 2020).

Collaboration with other healthcare providers is equally critical for program success. Pharmacists can work alongside physicians, nurses, and respiratory therapists to ensure a coordinated approach to smoking cessation. For example, physicians can refer patients to pharmacists for intensive counseling, while pharmacists can update physicians on patients' progress and any necessary adjustments to their care plans. Partnerships with public health organizations and community groups can also help raise awareness about the availability of pharmacist-led services, increasing patient uptake (Amalakuhan & Adams, 2015).

3.3. Challenges and Barriers to Implementation

Despite their proven effectiveness, pharmacist-led smoking cessation programs face several challenges that can impede their implementation and scalability. Many patients remain unaware of the smoking cessation services offered by pharmacists. Additionally, some individuals may underestimate pharmacists' expertise beyond medication dispensing, leading to underutilizing these programs. Public awareness campaigns can address these misperceptions and encourage more people to seek pharmacist-led support (A. Mohiuddin, 2019).

Pharmacists often juggle multiple responsibilities in their daily practice, making it difficult to dedicate sufficient time to smoking cessation counseling. Streamlining workflows and providing additional staffing support can help pharmacists prioritize these programs without compromising other duties. In many regions, smoking cessation services provided by pharmacists are not adequately reimbursed by healthcare systems or insurance plans (Pierucci et al., 2021). This lack of financial support can discourage pharmacists from offering these services. Advocacy efforts are needed to secure funding and policy changes recognizing pharmacist-led interventions' value (Amalakuhan & Adams, 2015).

Not all pharmacists have received specialized training in smoking cessation counseling, creating variability in service quality. Mandating training programs and offering incentives for certification can standardize and improve the delivery of these interventions. In diverse communities, cultural attitudes toward smoking and language differences can hinder effective communication between pharmacists and patients (Jumbe et al., 2022). Providing culturally sensitive materials and employing multilingual staff can help address these barriers. While telehealth has expanded the reach of pharmacist-led programs, some patients may lack the necessary technology or digital literacy to engage with these

services. Bridging the digital divide through community resources or simplified platforms can enhance accessibility (Crilly & Kayyali, 2020).

4. Future Directions

4.1. Innovations in Smoking Cessation

Emerging technologies and advancements in personalized medicine are transforming the landscape of smoking cessation, creating new opportunities for pharmacists to enhance their interventions. The integration of digital tools, such as mobile applications, wearable devices, and online platforms, is revolutionizing smoking cessation (Huang, Mulyasmita, & Rajagopal, 2016). Mobile apps designed to track progress, provide motivational messages, and offer behavioral strategies can complement pharmacist-led counseling. Wearable devices that monitor biomarkers, such as heart rate and blood pressure, can provide real-time feedback to patients, reinforcing their commitment to quit smoking. Telehealth platforms enable pharmacists to reach broader populations, including those in remote or underserved areas, ensuring continuity of care through virtual counseling and follow-up (Roski et al., 2019).

Advances in pharmacogenomics and personalized medicine are paving the way for tailored smoking cessation therapies. Pharmacists can utilize genetic testing to determine a patient's response to specific cessation medications, such as varenicline or nicotine replacement therapy. This precision approach minimizes adverse effects, enhances efficacy, and improves adherence to treatment plans. Additionally, personalized behavioral interventions, informed by patient preferences and psychological profiles, can address individual barriers to quitting (Wilson et al., 2019).

Artificial intelligence (AI) and data analytics hold significant potential in optimizing smoking cessation programs. AI-driven algorithms can predict patients' likelihood of relapse, allowing pharmacists to proactively address risk factors. Data analytics can also provide insights into population-level trends, helping pharmacists design targeted interventions for specific demographics (Boucher et al., 2021).

4.2. Policy and Funding Considerations to Scale Up Programs

Scaling up pharmacist-led smoking cessation programs requires robust policy support and sustainable funding mechanisms. Governments and healthcare authorities must recognize the critical role of pharmacists in tobacco control and integrate their services into national cessation strategies. Policies that expand pharmacists' scope of practice, such as allowing them to prescribe cessation medications, can enhance their capacity to deliver comprehensive care. Standardized guidelines and protocols for pharmacist-led interventions should be developed to ensure consistency and quality across different settings.

Adequate funding is essential to sustain and expand these programs. Governments and private insurers should include pharmacist-led smoking cessation services in reimbursement schemes, incentivizing pharmacists to offer these interventions. Public funding for training programs and infrastructure development, such as telehealth platforms and digital tools, can further support the scalability of these initiatives. Collaboration between public health organizations, private healthcare providers, and technology companies can drive innovation and resource mobilization. For instance, partnerships with app developers or wearable device manufacturers can facilitate technology integration into pharmacist-led programs, improving accessibility and patient engagement.

4.3. Areas for Further Research

Despite significant progress, several areas require further research to optimize pharmacist-led smoking cessation programs. While many studies focus on short-term quit rates, there is a need for research into the long-term effectiveness of these programs. Understanding the sustainability of abstinence over years, rather than months, can provide valuable insights into program design and follow-up strategies.

Research should explore the effectiveness of pharmacist-led interventions among diverse populations, including individuals with co-occurring mental health conditions, adolescents, and pregnant women. Tailored approaches may be required to address the unique challenges faced by these groups. Comprehensive economic evaluations are needed to quantify the cost-effectiveness of pharmacist-led programs across different healthcare systems. These studies can inform policymakers and funding bodies about the value of investing in these interventions.

Further investigation into novel delivery models, such as community-based collaborations or mobile health units, can identify effective ways to expand access to smoking cessation services. Research should also assess the feasibility and impact of integrating AI, wearable devices, and genetic testing into these programs.

Understanding the psychological and social factors influencing smoking behavior is crucial for designing effective interventions. Research into behavioral science applications, such as gamification or social incentives, can provide innovative tools for enhancing patient motivation and adherence. Smoking cessation is a global challenge, but cultural attitudes toward smoking vary widely. Research into the implementation and effectiveness of pharmacist-led programs in different cultural contexts can identify best practices and adapt interventions to local needs.

5. Conclusion

Pharmacist-led programs have demonstrated high quit rates, improved patient satisfaction, and cost-effectiveness compared to traditional smoking cessation methods. Clinical trials and observational studies consistently show that these interventions result in better outcomes due to pharmacists' ability to combine behavioral counseling with tailored pharmacotherapy. The variety of program models—including community pharmacy, hospital-based, telehealth, and workplace settings—enables wide applicability across different populations and healthcare environments.

Despite their success, challenges such as limited public awareness, inadequate reimbursement, and logistical barriers remain significant. Furthermore, the need for ongoing training, resources, and integration with other healthcare providers underscores the importance of a supportive ecosystem for these programs. Innovations such as digital tools, personalized medicine, and artificial intelligence offer exciting opportunities to enhance their reach and impact.

Pharmacists should seek training in evidence-based smoking cessation techniques, including behavioral counseling and the use of pharmacogenomics to tailor therapies. Regular participation in continuing education programs can ensure they stay informed about the latest advancements. Raising awareness about the availability and benefits of pharmacist-led smoking cessation programs is crucial. Pharmacists can engage in community outreach, collaborate with local health organizations, and use social media to reach potential patients. Tailoring interventions to individual needs, preferences, and barriers can increase the likelihood of success and improve patient satisfaction.

Healthcare systems should formally incorporate pharmacist-led cessation programs into primary care frameworks. This includes enabling referrals from other providers and ensuring continuity of care. Funding for training programs, digital tools, and telehealth platforms is essential to equip pharmacists with the resources needed to deliver high-quality care. Reimbursement policies must cover smoking cessation services provided by pharmacists to incentivize their participation and remove financial barriers for patients.

Policymakers should expand the roles of pharmacists, allowing them to prescribe smoking cessation medications independently. This policy shift would enable pharmacists to deliver more comprehensive care. Public health campaigns should emphasize the availability and effectiveness of pharmacist-led smoking cessation services, encouraging more individuals to seek help. Policymakers should allocate funds for research into novel technologies, behavioral strategies, and implementation models that can further enhance the effectiveness of these programs.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

- [1] Abdulsalim, S., Unnikrishnan, M. K., Manu, M. K., Alrasheedy, A. A., Godman, B., & Morisky, D. E. (2018). Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: a randomized controlled study. *Research in Social and Administrative Pharmacy*, 14(10), 909-914.
- [2] Alabkal, R. M. (2021). *Influence of pharmacist-led intervention on health outcomes and costs in hospital out-patients with type 2 diabetes and hypertension*. University of Bradford,
- [3] Amalakuhan, B., & Adams, S. G. (2015). Improving outcomes in chronic obstructive pulmonary disease: the role of the interprofessional approach. *International Journal of Chronic Obstructive Pulmonary Disease*, 1225-1232.
- [4] Atif, M., Hasan, S., Mushtaq, I., Javaid, S., Asghar, N., & Scahill, S. (2020). A qualitative study to explore the role of pharmacists in healthy weight management in adults in Pakistan: current scenario and future perspectives. *BMC Health Services Research*, 20, 1-13.

- [5] Bilano, V., Gilmour, S., Moffiet, T., d'Espaignet, E. T., Stevens, G. A., Commar, A., . . . Shibuya, K. (2015). Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. *The Lancet*, 385(9972), 966-976.
- [6] Boucher, E. M., Harake, N. R., Ward, H. E., Stoeckl, S. E., Vargas, J., Minkel, J., . . . Zilca, R. (2021). Artificially intelligent chatbots in digital mental health interventions: a review. *Expert Review of Medical Devices*, 18(sup1), 37-49.
- [7] Brett, K., Yeung, S. S., & Ford, C. (2019). Pharmacist-led interventions for tobacco smoking cessation: a review of clinical effectiveness and cost-effectiveness.
- [8] Ciccolo, J. T., & Busch, A. M. (2015). Behavioral interventions to enhance smoking cessation: A summary of the current evidence. *American Journal of Lifestyle Medicine*, 9(2), 92-104.
- [9] Crilly, P., & Kayyali, R. (2020). A systematic review of randomized controlled trials of telehealth and digital technology use by community pharmacists to improve public health. *Pharmacy*, 8(3), 137.
- [10] Gershkowitz, B. D., Hillert, C. J., & Crotty, B. H. (2021). Digital coaching strategies to facilitate behavioral change in type 2 diabetes: a systematic review. *The Journal of Clinical Endocrinology & Metabolism*, 106(4), e1513-e1520.
- [11] Greenhalgh, T., Macfarlane, F., Steed, L., & Walton, R. (2016). What works for whom in pharmacist-led smoking cessation support: realist review. *BMC medicine*, 14, 1-16.
- [12] Greer, N., Bolduc, J., Geurkink, E., Rector, T., Olson, K., Koeller, E., . . . Wilt, T. J. (2016). Pharmacist-led chronic disease management: a systematic review of effectiveness and harms compared with usual care. *Annals of internal medicine*, 165(1), 30-40.
- [13] Hilts, K. E., Corelli, R. L., Vernon, V. P., & Hudmon, K. S. (2022). Update and recommendations: Pharmacists' prescriptive authority for tobacco cessation medications in the United States. *Journal of the American Pharmacists Association*, 62(5), 1531-1537.
- [14] Huang, B. E., Mulyasmita, W., & Rajagopal, G. (2016). The path from big data to precision medicine. *Expert Review of Precision Medicine and Drug Development*, 1(2), 129-143.
- [15] Jones, L. K., Greskovic, G., Grassi, D. M., Graham, J., Sun, H., Gionfriddo, M. R., . . . Wright, E. A. (2017). Medication therapy disease management: Geisinger's approach to population health management. *American Journal of Health-System Pharmacy*, 74(18), 1422-1435.
- [16] Jumbe, S., Madurasinghe, V. W., James, W. Y., Houlihan, C., Jumbe, S. L., Yau, T., . . . Steed, L. (2022). STOP—a training intervention to optimise treatment for smoking cessation in community pharmacies: cluster randomised controlled trial. *BMC medicine*, 20(1), 212.
- [17] Mattingly, A. N., & Mattingly II, T. J. (2018). Advancing the role of the pharmacy technician: a systematic review. *Journal of the American Pharmacists Association*, 58(1), 94-108.
- [18] McCart, A. L. (2017). Evaluating work place wellness in greater Louisville's technology organizations: a case study.
- [19] Mohiuddin, A. (2019). The excellence of pharmacy service: Past, present and future. *International Journal of Clinical and Developmental Anatomy*, 5(2), 15-36.
- [20] Mohiuddin, A. K. (2020). *The role of the pharmacist in patient care: achieving high quality, cost-effective and accessible healthcare through a team-based, patient-centered approach*: Universal-Publishers.
- [21] Novins, D. K., Croy, C. D., Moore, L. A., & Rieckmann, T. (2016). Use of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities. *Drug and alcohol dependence*, 161, 214-221.
- [22] O'Reilly, E., Frederick, E., & Palmer, E. (2019). Models for pharmacist-delivered tobacco cessation services: a systematic review. *Journal of the American Pharmacists Association*, 59(5), 742-752.
- [23] Ogunbayo, O. J., Schafheutle, E. I., Cutts, C., & Noyce, P. R. (2015). A qualitative study exploring community pharmacists' awareness of, and contribution to, self-care support in the management of long-term conditions in the United Kingdom. *Research in Social and Administrative Pharmacy*, 11(6), 859-879.
- [24] Organization, W. H. (2017). *Tobacco control for sustainable development*: World Health Organization, Regional Office for South-East Asia.
- [25] Patel, M. S., & Steinberg, M. B. (2016). Smoking cessation. *Annals of internal medicine*, 164(5), ITC33-ITC48.

- [26] Perez-Warnisher, M. T., de Miguel, M. d. P. C., & Seijo, L. M. (2019). Tobacco use worldwide: Legislative efforts to curb consumption. *Annals of Global Health*, 85(1).
- [27] Pettit, N., Pope, I., Neuner, B., Lash, R., & Bernstein, S. L. (2022). A selective review of smoking cessation interventions in the emergency department. *Emergency Cancer Care*, 1(1), 5.
- [28] Pierucci, P., Santomasi, C., Ambrosino, N., Portacci, A., Diaferia, F., Hansen, K., . . . Carpagnano, G. E. (2021). Patient's treatment burden related to care coordination in the field of respiratory diseases. *Breathe*, 17(1).
- [29] Register, S. J., Harrington, K. F., Agne, A. A., & Cherrington, A. L. (2016). Effectiveness of non-primary care-based smoking cessation interventions for adults with diabetes: a systematic literature review. *Current Diabetes Reports*, 16, 1-9.
- [30] Roski, J., Hamilton, B., Chapman, W., Heffner, J., Trivedi, R., Del Fiol, G., . . . Klann, J. (2019). How artificial intelligence is changing health and healthcare. *Artificial intelligence in health care: The hope, the hype, the promise, the peril*. Washington DC: National Academy of Medicine, 58.
- [31] Rukavena, M. A. (2021). *Improving Pharmacy-Led Smoking Cessation Practices at a Federally Qualified Health Center*. The University of Arizona,
- [32] Schafer, J. J., Gill, T. K., Sherman, E. M., McNicholl, I. R., & Hawkins, B. (2016). ASHP guidelines on pharmacist involvement in HIV care. *American Journal of Health-System Pharmacy*, 73(7), 468-494.
- [33] Trapskin, P. J., Sheehy, A., Creswell, P. D., McCarthy, D. E., Skora, A., Adsit, R. T., . . . Iglar, E. (2022). Development of a pharmacist-led opt-out cessation treatment protocol for combustible tobacco smoking within inpatient settings. *Hospital Pharmacy*, 57(1), 167-175.
- [34] VanFrank, B., & Presley-Cantrell, L. (2021). A comprehensive approach to increase adult tobacco cessation. *JAMA*, 325(3), 232-233.
- [35] Wilson, S. M., Thompson, A. C., Currence, E. D., Thomas, S. P., Dedert, E. A., Kirby, A. C., . . . Beckham, J. C. (2019). Patient-informed treatment development of behavioral smoking cessation for people with schizophrenia. *Behavior therapy*, 50(2), 395-409.